Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer

PURPOSE: Atypical, non-V600 BRAF (aBRAF) mutations represent a rare molecular subtype of metastatic colorectal cancer (mCRC). Preclinical data are used to categorize aBRAF mutations into class II (intermediate to high levels of kinase activity, RAS independent) and III (low kinase activity level, RA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Johnson, Benny, Loree, Jonathan M., Jacome, Alexandre A., Mendis, Shehara, Syed, Muddassir, Morris II, Van K., Parseghian, Christine M., Dasari, Arvind, Pant, Shubham, Raymond, Victoria M., Vilar, Eduardo, Overman, Michael, Kee, Bryan, Eng, Cathy, Raghav, Kanwal, Kopetz, Scott
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446507/
https://ncbi.nlm.nih.gov/pubmed/32914034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados